CYPHERPUNK TECHNOLOGIES INC. Liabilities Assumed
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Liabilities Assumed of $928.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:LiabilitiesAssumed1 · last filed 2025-03-26
- CYPHERPUNK TECHNOLOGIES INC. liabilities assumed for the quarter ending 2023-12-31 was $0.00.
- CYPHERPUNK TECHNOLOGIES INC. liabilities assumed for the quarter ending 2023-09-30 was $0.00.
- CYPHERPUNK TECHNOLOGIES INC. liabilities assumed for the quarter ending 2023-06-30 was $0.00.
- CYPHERPUNK TECHNOLOGIES INC. liabilities assumed for the quarter ending 2023-03-31 was $928.00K.
- CYPHERPUNK TECHNOLOGIES INC. liabilities assumed for fiscal 2023 was $928.00K.
| Period end | Liabilities Assumed 3 month | Liabilities Assumed 6 month | Liabilities Assumed 9 month | Liabilities Assumed 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $0.00 derived: sum of 2 quarters · filed 2025-03-26 | $0.00 derived: sum of 3 quarters · filed 2025-03-26 | $928.00K 10-K · filed 2025-03-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $928.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $928.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $928.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |